Overview
PCRX market data
Price History
PCRX price chart
Valuation & Profitability
- P/E (TTM)
- 199.62 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.80 – $27.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1K · P/B 1.61 · P/S 1.40.
Company news
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026Globenewswire Inc · Jul 22, 2026, 12:15 PM
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jul 8, 2026, 12:15 PM
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price TargetBenzinga · Jul 1, 2026, 12:25 PM
Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outpatient Settings, Including Hospital Outpatient Departments And Ambulatory Surgery CentersBenzinga · Jul 1, 2026, 12:10 PM
Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140MBenzinga · Jun 30, 2026, 11:40 AM
8-K filing — Pacira BioSciences, Inc. (PCRX)SEC EDGAR · Jun 30, 2026, 11:31 AM
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsightGlobenewswire Inc · Jun 15, 2026, 5:15 PM
Pacira BioSciences Announces Findings From Real-World Study Evaluating Outcomes Associated With Use Of EXPAREL Following Outpatient Total Shoulder Arthroplasty In Medicare Advantage PatientsBenzinga · May 27, 2026, 12:04 PM